Skip to content

Comparing pregabalin and gabapentin for pain relief after head and neck cancer surgeries- a observational study.

Comparison of efficacy of pre-emptive pregabalin and gabapentin on postoperative pain in major head and neck cancer surgeries. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/04/085077
Enrollment
66
Registered
2025-04-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Department of Anaesthesiology and Critical Care , K.S HEGDE MEDICAL ACADEMY
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients with confirmed diagnosis of head and neck cancer. 2 Patients belonging to ASA grade I II and III

Exclusion criteria

Exclusion criteria: 1 Patient refusal. 2 Patients with previous severe adverse reaction to Pregabalin and Gabapentin. 3 Patients with renal impairment. 4 Patients already on opioids. 5 Patients taking Gabapentin or Pregabalin for other medical purposes.

Design outcomes

Primary

MeasureTime frame
To compare the intensity of pain among the two groups in the postoperative period, i.e., at 1hr, 2hr, 4hr, 6hr, 12hr and 24hr Time for first rescue analgesic.Timepoint: Group G: Gabapentin capsule 600 mg Group PG: Pregabalin capsule 150 mg with sips of water 1 hour before the expected time of induction of anaesthesia.

Secondary

MeasureTime frame
Postoperative nausea & vomiting (PONV). Dizziness Sedation in the first 24 hours postoperatively. Timepoint: The total dose of rescue analgesic needed in the first 24 h of the postoperative period will be recorded. The sedation score will be assessed by the Ramsay sedation assessment scale. Any side effects such as dizziness, nausea, vomiting, headache & respiratory depression will be noted.

Countries

India

Contacts

Public ContactGAYATHRI BHAT

K.S HEGDE MEDICAL ACADEMY

gaibhat@gmail.com9448467181

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026